title: Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase.
authors.affiliation: AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK. john.cumming@astrazeneca.com
authors.forename: John G
authors.initials: JG
authors.lastname: Cumming
authors.forename: Caroline L
authors.initials: CL
authors.lastname: McKenzie
authors.forename: Stuart G
authors.initials: SG
authors.lastname: Bowden
authors.forename: Douglas
authors.initials: D
authors.lastname: Campbell
authors.forename: David J
authors.initials: DJ
authors.lastname: Masters
authors.forename: Jason
authors.initials: J
authors.lastname: Breed
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Jewsbury
mesh_terms: D000255:Adenosine Triphosphate / Q000737:chemistry; D000284:Administration, Oral; D000814:Aniline Compounds / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology; D018501:Antirheumatic Agents / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology; D001665:Binding Sites; D001682:Biological Availability; D018360:Crystallography, X-Ray; D006801:Humans; D066298:In Vitro Techniques; D008958:Models, Molecular; D011485:Protein Binding; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D011799:Quinazolines / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D015398:Signal Transduction; D013329:Structure-Activity Relationship; D013997:Time Factors; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D000814:Aniline Compounds; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D011743:Pyrimidines; D011799:Quinazolines; D000255:Adenosine Triphosphate; D048051:p38 Mitogen-Activated Protein Kinases